SkinBioTherapeutics Announces Warrant Exercise
Why we think this is neutral
The RNS announcement is a routine update on the exercise of warrants and changes to the company's total voting rights. It does not contain any significant news about the company's trading, financials, or operations that would warrant a stronger sentiment score.
Key Points
- Warrant exercise notice received from Macquarie for 250,000 ordinary shares
- New ordinary shares to be admitted to trading on AIM on or around 21 March 2025
- Total issued shares and voting rights to increase to 231,975,383
Summary
The life science company announces the exercise of 250,000 warrants, resulting in the issuance of new ordinary shares.
SkinBioTherapeutics plc (AIM: SBTX), the life science business focused on skin health, has announced that it received an Exercise Notice from Macquarie for 250,000 ordinary shares at £0.2043 per share. The new ordinary shares will be admitted to trading on AIM on or around 21 March 2025, and the total number of issued shares and voting rights in the company will increase to 231,975,383.
GENERAL UPDATE